Last Updated : August 22, 2024
Details
FilesGeneric Name:
nab-paclitaxel
Project Status:
Active
Therapeutic Area:
Gastrointestinal cancer
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0360-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
In combination with gemcitabine for the adjuvant treatment of pancreatic cancer.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Submission received | 12-Feb-2024 |
---|---|
Review initiated | 13-Feb-2024 |
Expert committee meeting (initial) | 04-Jul-2024 |
Draft recommendation posted for stakeholder feedback | 01-Aug-2024 |
End of feedback period: | 16-Aug-2024 |
Files
Last Updated : August 22, 2024